Improved Discount Helps Lilly Secure English Funding For Verzenios
CDK4/6 Inhibitor Ibrance Has Not Yet Been Reappraised by NICE
Verzenios is now the second CDK4/6 inhibitor for advanced breast cancer that can be used routinely on England’s National Health Service in patients in a second-line setting.
